LabMedica

Download Mobile App
Recent News Expo
Medica 2025
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ebola Rapid Lateral Flow Test Previewed at the 2015 AACC Annual Meeting

By LabMedica International staff writers
Posted on 27 Jul 2015
Image: The AtomoRapid lateral flow immunoassay diagnostic platform (Photo courtesy of Atomo Diagnostics).
Image: The AtomoRapid lateral flow immunoassay diagnostic platform (Photo courtesy of Atomo Diagnostics).
A novel rapid point-of-care assay for the diagnosis of Ebolavirus infection was introduced at the 2015 AACC Annual Meeting & Clinical Lab Expo (Atlanta, GA, USA).

BBI Solutions (Cardiff, United Kingdom), a biotech company that supplies a range of mouse monoclonal antibodies for detecting the Ebola virus, announced from its booth (3665) at the AACC Annual meeting that that it would soon release a rapid test for Ebola in association with the technology transfer company Ploughshare Innovations (Stockbridge, United Kingdom).

The test is built around the highly regarded Atomo Diagnostics (Sydney, Australia) lateral flow technology and provides a result in approximately 20 minutes. Five Ebola antibodies against the Zaire and Sudan strains of Ebolavirus have been tested successfully with this system. BBI Solutions also provides a panel comprising 13 different monoclonal antibodies, to the Zaire and Sudan strains.

The lateral flow test has already been evaluated in the field. In trials in Sierra Leone a 100% detection rate was achieved for 138 participants. At low positive levels the test achieved 100% sensitivity and 92% specificity, and at a high positive, 100% sensitivity and 97% specificity. This performance suggests that the BBI Solutions assay is potentially more sensitive and specific than other lateral flow or dipstick type assays currently available.

Leigh Thomas, chief commercial officer at BBI Solutions, said, “BBI has developed high performance lateral flow tests for some of the world’s leading diagnostic companies for over 25 years. Our expertise and flexibility has allowed us to quickly deploy a team and develop a rapid test in nine months which, based on field testing, promises to have an immediate and positive impact on the Ebola crisis. We are pleased that our test will meet an immediate need in the field and ultimately improve the lives of others.”

Related Links:
2015 AACC Annual Meeting & Clinical Lab Expo
BBI Solutions
Atomo Diagnostics


New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Pipette
Accumax Smart Series
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer

Channels

Hematology

view channel
Image: Sickle cell disease patients with higher levels of RMVs, AMVs, and EMVs were found to have more severe disease (Photo courtesy of Adobe Stock)

Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients

Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more

Microbiology

view channel
Image: The rapid diagnostic test is being piloted across three UK hospitals (Photo courtesy of Imperial College Healthcare)

15-Minute Blood Test Diagnoses Life-Threatening Infections in Children

Distinguishing minor childhood illnesses from potentially life-threatening infections such as sepsis or meningitis remains a major challenge in emergency care. Traditional tests can take hours, leaving... Read more
GLOBE SCIENTIFIC, LLC